| Q38609182 | A pregnant patient with a positive hepatitis B surface antigen |
| Q35689607 | A treatment algorithm for the management of chronic hepatitis B virus infection in the United States |
| Q37351512 | Acute hepatitis B or exacerbation of chronic hepatitis B-that is the question |
| Q45843347 | Acute viral hepatitis in chronic carriers of hepatitis B virus: different patterns in different places |
| Q36828542 | Alpha-interferon therapy for chronic hepatitis B virus infection in children and Oriental patients |
| Q35840548 | Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis |
| Q35840956 | Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis |
| Q45853311 | Assay of hepatitis B virus DNA by polymerase chain reaction and its relationship to pre-S- and S-encoded viral surface antigens |
| Q41600191 | Challenges in the management of chronic HBV infection in West Africa: The clinician's perspective |
| Q41837714 | Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children |
| Q40612969 | Chronic hepatitis B acquired in childhood: unanswered questions and evolving issues |
| Q46959082 | Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study |
| Q35078029 | Chronic hepatitis B in children with or without malignancies: a 13-year follow-up |
| Q45352194 | Chronic hepatitis B virus (HBV) infection in children: 25 years' experience |
| Q34002160 | Chronic hepatitis B. |
| Q35589366 | Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients |
| Q30358894 | Current role of transient elastography in the management of chronic hepatitis B patients |
| Q36496783 | Diagnostic accuracy of serum biochemical fibrosis markers in children with chronic hepatitis B evaluated by receiver operating characteristics analysis |
| Q33829957 | Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load |
| Q55456475 | Epidemiology and prevention of hepatitis B virus infection. |
| Q45512396 | Estimates of chronic hepatitis B virus infection in Australia, 2000. |
| Q36532429 | Genetic variation in HBV infection: genotypes and mutants |
| Q44198141 | HBV infection in indigenous children, 20 years after immunization in Taiwan: a community-based study |
| Q44096901 | HBV-DNA-related hepatocellular carcinoma occurring in childhood. Report of three cases |
| Q38151076 | Hepatitis B and C in the armed forces |
| Q38024218 | Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: Findings from the Antiretroviral Pregnancy Registry |
| Q93140478 | Hepatitis B virus infection in children |
| Q45764193 | High degree of conservation in the hepatitis B virus core gene during the immune tolerant phase in perinatally acquired chronic hepatitis B virus infection |
| Q61770450 | Historia natural y manifestaciones clínicas de la hepatitis B crónica |
| Q34416274 | Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection |
| Q40208984 | Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B. |
| Q45849818 | Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection |
| Q45764431 | Interferon-alpha 2b treatment in hepatitis B carriers. Effect on hepatitis B virus DNA levels in children infected with different genotypes |
| Q36153966 | KASL Clinical Practice Guidelines: Management of chronic hepatitis B |
| Q26752475 | KASL clinical practice guidelines: management of chronic hepatitis B |
| Q42287464 | Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: A prospective cohort study with paired transient elastography examination |
| Q45854065 | Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood |
| Q27000080 | Management of Chronic Hepatitis B: Canadian Association for the Study of the Liver Consensus Guidelines |
| Q36849343 | Management of chronic hepatitis B: consensus guidelines |
| Q46762343 | Management of the Hepatitis B Carrier: Handling all aspects of the infection |
| Q58236488 | Morbidity and mortality from chronic hepatitis B virus infection in family members of patients with malignant and nonmalignant hepatitis B virus–related chronic liver diseases |
| Q37278090 | Natural history and clinical management of chronic hepatitis B virus infection in children |
| Q34036650 | Natural history of chronic hepatitis B: phases in a complex relationship |
| Q35295393 | Natural history of hepatitis B in perinatally infected carriers |
| Q35543568 | Natural history of hepatitis b and outcomes after liver transplantation |
| Q45788161 | Naturally occurring hepatitis B virus core gene mutations |
| Q33671155 | Naturally occurring variants of hepatitis B virus |
| Q35628953 | New aspects on the natural history of chronic hepatitis B infection: implication for therapy |
| Q43645523 | Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. |
| Q77872090 | Outcome of chronic hepatitis B in children with normal transaminase levels |
| Q45274404 | Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management |
| Q38491309 | Rethinking the pathogenesis of hepatitis B virus (HBV) infection |
| Q80692806 | Seroprevalence of hepatitis B viral markers among freshmen--20 years after mass hepatitis B vaccination program in Taiwan |
| Q45867916 | Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection |
| Q44594235 | The Lack of Effect of Therapeutic Vaccination With a Pre-S2/S HBV Vaccine in the Immune Tolerant Phase of Chronic HBV Infection |
| Q37709066 | The Rate of Conversion from Immune-tolerant Phase to Early Immune-clearance Phase in Children with Chronic Hepatitis B Virus Infection. |
| Q28073299 | The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics |
| Q55428306 | The management of chronic viral hepatitis: A Canadian consensus conference 2004. |
| Q64132783 | The natural history of chronic hepatitis B virus infection |
| Q36711602 | The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). |
| Q43605323 | Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study. |
| Q37201573 | Treatment of chronic hepatitis B infection: an update of Swedish recommendations |
| Q33988072 | Treatment of chronic hepatitis B virus infection in special groups of patients: decompensated cirrhosis, immunosuppressed and paediatric patients |
| Q89523215 | Unresolved issues of immune tolerance in chronic hepatitis B |
| Q33588921 | Update on diagnosis, management, and prevention of hepatitis B virus infection |
| Q40966818 | Update on viral hepatitis in children |
| Q33624566 | Viral hepatitis |
| Q40567818 | Viral hepatitis in children with renal disease |
| Q40687503 | Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study |